INTRODUCTION {#sec1-1}
============

Intracranial solitary fibrous tumors (iSFT) are rare tumors. Series with 5, 18, and 24 patients have been published\[[@ref1][@ref4][@ref8]\] as well as several case reports with 1--2 patients.\[[@ref2][@ref3][@ref5][@ref6][@ref7][@ref9]\] Two of the case reports present the outcome following radiosurgery\[[@ref5][@ref6]\] in a total of three patients. The longest follow-up (FU) in those three patients was 4 years. In order to add to our understanding of iSFT, we retrospectively reviewed our patients with iSFT who underwent single-session radiosurgery.

METHODS {#sec1-2}
=======

We retrospectively reviewed the patient charts of the patients who underwent Gamma Knife radiosurgery (GKRS) for iSFT at Klinik Im Park, Zurich between 1994 and 2009 and whose surgical- or radiosurgical-treatments were performed by one or both of the authors (TM, RR). The diagnosis of iSFT was based on histology.

RESULTS {#sec1-3}
=======

From 1994 to 2009, two patients underwent GKRS for iSFT at Klinik Im Park.

Case 1 {#sec2-1}
------

A 57-year-old male patient initially underwent GKRS in 1997 for what was believed to be a parasagittal meningioma located over the right central region. Throughout the 17-year FU, the patient underwent altogether five radiosurgical treatments and two craniotomies for iSFT and its local recurrences. The choice of open surgery or radiosurgery depended on the patient\'s preferences. In 2005, 8 years after the initial GKRS, the patient underwent the first craniotomy for local tumor recurrence. The histological diagnosis was then meningioma WHO I. In 2010, 13 years after the initial GKRS, the patient underwent another craniotomy for tumor recurrence. Histology then revealed an SFT. Immunohistochemistry showed positive expression for Vimentin, CD34, and CD99 and negative expression for Epithelial membrane antigen, Carcinoembryonic antigen (EMA) Pancreatin, and S-100. The proliferation marker MIB 1 was expressed in 2--5% of the nuclei. The previous histology was reevaluated and the diagnosis of SFT was retrospectively confirmed for the initial surgery. The patient developed liver metastases 13 years after the initial GKRS. The liver metastases were first biopsied and then removed in liver segments II, VI, VII, and VIII. Histology was compatible with SFT: Positive expression for CD34, CD99, and BCL2; negative expression for CD20, CD3, smooth muscle Actine, S-100, HMB-45, WT1, Lu-5, CD10, CD138, Inhibine, DOG-1, Desmine, Synaptophysine, CD117, and EMA. A total of 13.5 years following GKRS, pulmonary metastases were discovered on computed tomography (CT) scan. The patient did not undergo biopsy or surgery for the pulmonary metastases. The patient did not undergo any additional systemic oncological therapy or any radiotherapy for the distant metastases since it was felt that there were no promising local or systemic therapies to be offered. Therefore, the patient underwent a wait and scan FU regime for the distant metastases. The radiosurgical procedures were done with two different technologies since the hospital changed the radiosurgical equipment from Gamma Knife to CyberKnife in 2009. Progression-free survival (PFS) following the various radiosurgical procedures was 2--5 years and 0.75--2 years following the various open surgical procedures. The patient is now 74 years old and alive. He maintained a Karnofsky performance score (KPS) 100 during the 17-year FU. At present, he has a slight spacticity of his left leg and is still skiing. The details of the clinical course are listed in [Table 1](#T1){ref-type="table"}, the tumor characteristics in [Table 2](#T2){ref-type="table"}, the radiosurgical treatment characteristics in [Table 3](#T3){ref-type="table"}, and the planning images for the last radiosurgical treatment with the CyberKnife are illustrated in [Figure 1](#F1){ref-type="fig"}.
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![Screenshot of the CyberKnife planning for the latest radiosurgical treatment of a small local parasagittal tumor recurrence with axial, sagital, and coronal views. The tumor volume was 0.2 cc and the Prescription Dose was 14 Gy delivered to the 73% isodose line. The 14 Gy-, 10 Gy-, 8 Gy-, and 4 Gy-isodose lines are color coded](SNI-5-590-g004){#F1}

Case 2 {#sec2-2}
------

A 70-year-old female patient had a history of resection of a malignant melanoma of the right thigh and postoperative local radiotherapy when she was 35 years old. At age 70, she underwent resection for a tumor of the right tentorium. Histology revealed an SFT with positive expression for CD34 and negative staining for EMA and Glial fibrillary acidic protein (GFAP) Throughout the 9-year FU, she underwent two craniotomies and one radiosurgical treatment for iSFT. PFS was 3 years following the initial surgery. PFS was at least 2 years following GKRS; the patient did not show up for FU until 6 years after GKRS. Nine years after the initial surgery and 6 years after GKRS, a large local tumor recurrence was seen on MRI and the patient opted for another craniotomy. Histology revealed again an SFT with positive expression for CD34 and negative staining for EMA and GFAP. The patient is alive and is now aged 79 years. She maintained a KPS 100 during the 9-year FU with no focal neurological deficits. The details of the clinical course are listed in [Table 1](#T1){ref-type="table"}, the tumor characteristics in [Table 2](#T2){ref-type="table"}, the radiosurgical treatment characteristics in [Table 3](#T3){ref-type="table"}, and the planning images for the radiosurgical treatment with the Gamma Knife are illustrated in [Figure 2](#F2){ref-type="fig"}.

![Screenshot of the Gamma Knife planning for a small local tumor recurrence with axial, sagital, and coronal views. The tumor volume was 1.2 cc and the Prescription Dose was 14 Gy to the 50%-isodose line. The tumor margin is contoured with the red line, the 50%-isodose line is the yellow line](SNI-5-590-g005){#F2}

DISCUSSION {#sec1-4}
==========

To our knowledge, this is the longest FU of patients who underwent surgery and radiosurgery for iSFT. It seems that a close FU and a combination of surgery and radiosurgery lead to promising results in such patients. Small tumor recurrences may be best treated by radiosurgery and larger tumor recurrences by open microsurgery even though a rather large tumor volume of 21.1 cc was treated successfully by GKRS in Case 1, which was followed by a 5-year PFS. Tumor volumes treated with radiosurgery ranged from 0.2 to 21.1 cc. In our patients, a prescription dose of 12-15 Gy to the tumor margin lead to a PFS for intervals ranging from 2 to 5 years. Repeat radiosurgery was tolerated without any problems. One of our two patients developed distant metastases 13 years after the occurrence of iSFT. SFT seem to have a high tendency for local tumor recurrence. SFT seem to respond well to radiosurgery and they seem to have a rather good long -term prognosis. We therefore advocate for a close FU of patients with iSFT. Whenever tumor recurrence is evident on MRI, patients should be offered radiosurgery or open microsurgery.

CONCLUSION {#sec1-5}
==========

Both patients with iSFT are long-term survivors with a FU of 9 and 17 years, respectively. Patients with iSFT seem to have a rather good prognosis if they are followed closely with MRIs and if tumor recurrences are treated when they become evident. A combination of surgery and radiosurgery seems to lead to a favorable long-term outcome in patients with iSFT.
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